SFJ Pharma Selling Geographic And Indication Expansion, One Compound At A Time
This article was originally published in PharmAsia News
Pfizer Inc. and Eisai Co.'s downsized R&D budgets seek no-risk solutions with SFJ Pharma.
You may also be interested in...
Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.